SMA 50 společnosti Neovacs S.A
Jaká je hodnota metriky SMA 50 společnosti Neovacs S.A?
Hodnota metriky SMA 50 společnosti Neovacs S.A. je €0 +100.00%
Jaká je definice metriky SMA 50?
SMA 50 je průměrná cena akcií z posledních 50 dnů vypočítaná jako nevážený průměr předchozích 50 závěrečných cen.
Simple moving average of 50 days for a stock is an unweighted moving average over the past 50 days. Moving averages will always exhibit a lag and the longer the period used for averaging the greater the lag will be. Because of the large amounts of data considered when calculating a long-term moving average, it takes a considerable amount of movement in the market to cause the moving average to change its course.
Using a moving average to confirm a trend in price is one of the most basic, yet effecting ways of using the indicator. Moving averages take into account what has already happened and a whole range of past events, which makes them such a good technical analysis tool for trend confirmations. Generally, a long-term moving average that is clearly on the upswing is a confirmation of a bullish trend. Conversely, a long-term moving average that is clearly on the downswing is a confirmation of a bearish trend.
SMA 50 společností v sektoru Health Care sektor na EURONEXT ve srovnání se společností Neovacs S.A
Čemu se věnuje společnost Neovacs S.A?
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Firmy s metrikou sma 50 podobnou společnosti Neovacs S.A
- Hodnota metriky SMA 50 společnosti Neovacs S.A je €0 +100.00%
- Hodnota metriky SMA 50 společnosti EVmo Inc je $0 +99.75%
- Hodnota metriky SMA 50 společnosti Blue Capital Reinsurance Ltd je $0 -Inf%
- Hodnota metriky SMA 50 společnosti Kaleido Biosciences Inc je $0 +59.40%
- Hodnota metriky SMA 50 společnosti Yangtze River Port and Logistics Ltd je $0 +28.25%
- Hodnota metriky SMA 50 společnosti iFresh Inc je $0 +0.00%
- Hodnota metriky SMA 50 společnosti Aridis Pharmaceuticals Inc je $0 +83.25%